PCJ Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthRapid sequential revenue growth indicates that ZEVASKYN is beginning to convert clinical adoption into commercial demand. Continued treatment activity and recognized revenue could establish a durable growth platform as more physicians and qualified centers gain experience with the therapy.
Expanding Treatment-center NetworkExpansion to an eighth qualified treatment center broadens patient access and increases the infrastructure available to support future treatments. A larger network can strengthen physician adoption, improve geographic coverage, and support more consistent commercial growth over the next several quarters.
Strategic Reimbursement ValidationCMS NTAP approval provides a structural reimbursement pathway that may improve hospital economics for administering ZEVASKYN, particularly within Medicare. The award also represents external validation of the therapy’s clinical improvement and could reduce a major barrier to broader adoption.
Bears Say
Heavy Cash Burn And Ongoing LossesMaterially negative operating and free cash flow show that the current business is not yet self-funding. Unless treatment volume and margins improve substantially, Abeona may continue relying on external financing, which can constrain strategic flexibility and pressure shareholder equity.
Manufacturing Yield And Billing RiskManufacturing failures directly reduce recognized revenue while Abeona still absorbs the cost of goods sold for nonbillable treatments. Repeated yield or specification problems could make revenue less predictable, delay the commercial ramp, and prevent expected operating leverage from developing.
Regulatory Assay UncertaintyThe unresolved Pan-CK assay specification issue creates regulatory and operational uncertainty around commercial manufacturing. FDA review or revised requirements could delay production, increase compliance work, and worsen treatment scheduling and revenue volatility while the company seeks resolution.
Abeona Therapeutics News
PCJ FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is CHF261.45M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 55 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Aug 13, 2026. The company reported -CHF0.289 earnings per share for the quarter, missing the consensus estimate of -CHF0.191 by -CHF0.097.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Abeona Therapeutics have?
Currently, no data Available
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -CHF0.289 in its last earnings report, missing expectations of -CHF0.191. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in CH:PCJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF18.10 (― Upside)
CHF18.10 (― Upside)
Blogger Sentiment
Bullish
CH:PCJ Sentiment 92%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth CHF808.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
PCJ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights clear commercial progress: 31% quarter-over-quarter revenue growth, expansion to 7 QTCs, 12 patients treated since launch, improved average manufacturing yields in commercial runs, a strong balance sheet ($146.8M) and a significant NTAP reimbursement win that validates the therapy. However, material operational and manufacturing challenges (one low-yield and one out-of-spec batch causing unrevenueed treatments), logistical fragility around the 84-hour shelf life, regulatory work to revisit an assay specification, and continued GAAP losses introduce meaningful near-term execution risk and revenue volatility. Management has implemented clearer reporting metrics and is pursuing operational learnings to mitigate these issues, but variability in site activation and sensitivity to manufacturing yield remain key risks to the revenue ramp.View all CH:PCJ earnings summaries